Back to list

ACADIA Neurodegenerative Disease and Psychosis

University of North Carolina at Chapel Hill


Description

To assess the safety and tolerability of pimavanserin compared to placebo in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease


Keywords:

Alzheimer's, Behavior, Dementia, Elderly, Neurological Disorders, Older Adults


Category:

Drug or Biologic
Phase:3

Qualifications

 


Age
60 - 99 years


Gender
Any


Study Population

This study will be conducted as a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in adult and elderly, greater than or equal to 60 yo, subjects with neuropsychiatric symptoms related to neurodegenerative disease.


Investigator

Daniel Kaufer
Assoc Professor with tenure
Neurology

For questions, contact:

Luigi Troiani
troianil@neurology.unc.edu
(919) 843-2579
Visit Website

Recruitment Period End

May 31, 2021

Location

Primary Location
UNC Healthcare Adult Neurology Clinic
194 Finley Golf Course Rd, Chapel Hill, NC 27517, USA
Secondary Location
NA

Study Qualifications

Gender Any

Age Range 60 - 99 years

Participant qualification(s) Must have neuropsychiatric symptoms, associated with a neurodegenerative disease, severe enough to warrant treatment with an antipsychotic agent, Neurodegenerative diseases: Parkinson's dementia Dementia with Lewy bodies Alzheimer's disease Frontotemporal degeneration spectrum disorders

Not eligible if: Has neuropsychiatric symptoms primarily attributed to current delirium or substance abuse Is in hospice or receiving end-of-life palliative care History of epilepsy History of HIV or Hepatitis C infection

Number of Visits

    » 7 In person visit(s)

    1 Screening, 1 Baseline, 5 Clinic, 1 possible CT or MRI if none in the past 3 years

    » 1 Remote visit(s)

    1 phone

Participation Period

12 weeks

Compensation

$84 for completed study visits and unscheduled visits. $69.30 for travel for scheduled and unscheduled study visits

By clicking I am interested, your contact information will be sent to the researcher/study coordinator for this study. The coordinator will respond by email with additional information on how to proceed.